GeneDx (WGS) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WGS shares.
View WGS analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for GeneDx's stock. Their WGS share price forecasts range from $33.00 to $99.00. On average, they predict the company's stock price to reach $74.25 in the next year. This suggests a possible upside of 1,985.7% from the stock's current price.
View analysts price targets for WGS or view top-rated stocks among Wall Street analysts.

GeneDx's stock was trading at $8.7054 on January 1st, 2023. Since then, WGS shares have decreased by 59.1% and is now trading at $3.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our WGS earnings forecast.

GeneDx Holdings Corp. (NASDAQ:WGS) announced its earnings results on Tuesday, August, 8th. The company reported ($1.65) earnings per share for the quarter, missing analysts' consensus estimates of ($1.47) by $0.18. The firm earned $48.71 million during the quarter, compared to the consensus estimate of $45.60 million. GeneDx had a negative trailing twelve-month return on equity of 134.48% and a negative net margin of 208.96%.

GeneDx's stock reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

GeneDx issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$220.00 million, compared to the consensus revenue estimate of $208.23 million.

GeneDx trades on the NASDAQ under the ticker symbol "WGS."

GeneDx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Casdin Capital LLC (12.10%), Oracle Investment Management Inc. (3.38%), Marshall Wace LLP (2.97%), Gagnon Securities LLC (1.42%), BlackRock Inc. (1.03%) and Goldman Sachs Group Inc. (0.85%). Insiders that own company stock include Anthony Prentice, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard C Pfenniger Jr, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone.
View institutional ownership trends.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WGS stock can currently be purchased for approximately $3.56.

GeneDx (NASDAQ:WGS) has a market capitalization of $91.74 million and generates $234.69 million in revenue each year.

The company employs 1,100 workers across the globe.

GeneDx's mailing address is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. The official website for the company is sema4.com. The company can be reached via phone at 800-298-6470 or via email at investors@sema4.com.